Spago Nanomedical AB (publ) (STO:SPAGO)

Market Cap	72.77M -8.7%
Revenue (ttm)	4.38M -34.9%
Net Income	-25.92M
EPS	-0.06
Shares Out	661.57M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	900,894
Open	0.1125
Previous Close	0.1100
Day's Range	0.1070 - 0.1125
52-Week Range	0.0842 - 0.4600
Beta	1.30
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 21, 2026

About Spago Nanomedical AB

Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under preclinical development stage. The company wa...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 7
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SPAGO

Financial Performance

In 2025, Spago Nanomedical AB's revenue was 4.47 million, a decrease of -32.85% compared to the previous year's 6.66 million. Losses were -26.55 million, -18.32% less than in 2024.